Clinical Trials · NCT04952779
Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 750
- Start date
- Jun 2021
- Locations
- 32 sites, South Korea
- Primary endpoint
- Incidence of Adverse Events (AEs) by preferred term